Cantor’s Mara Goldstein believes the valuation of the $1.7 billion takeover by Roche is sound, and does not think another bid for RXDX is forthcoming.
Cantor’s Mara Goldstein notes that RXDX’s next transaction could be ALK, calling the deal with Roche quite a “gift” for shareholders.
ROS1-Positive interim data raises Mara Goldstein’s conviction.
Ignyta Inc (NASDAQ:RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S.
I have written a lot of articles over the years concerning my biotech investments and thankfully have done pretty well anticipating good entry …
